Free Trial

Immatics (IMTX) Competitors

Immatics logo
$6.56 +0.11 (+1.71%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$6.56 0.00 (0.00%)
As of 07/25/2025 05:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IMTX vs. CRNX, MOR, ALVO, MIRM, CPRX, GMTX, AMRX, NAMS, RARE, and OGN

Should you be buying Immatics stock or one of its competitors? The main competitors of Immatics include Crinetics Pharmaceuticals (CRNX), MorphoSys (MOR), Alvotech (ALVO), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), Gemini Therapeutics (GMTX), Amneal Pharmaceuticals (AMRX), NewAmsterdam Pharma (NAMS), Ultragenyx Pharmaceutical (RARE), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry.

Immatics vs. Its Competitors

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Immatics (NASDAQ:IMTX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Crinetics Pharmaceuticals has a net margin of 0.00% compared to Immatics' net margin of -14.73%. Immatics' return on equity of -4.52% beat Crinetics Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Crinetics PharmaceuticalsN/A -30.95% -28.12%
Immatics -14.73%-4.52%-3.34%

Immatics has higher revenue and earnings than Crinetics Pharmaceuticals. Immatics is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crinetics Pharmaceuticals$760K3,817.85-$298.41M-$3.82-8.11
Immatics$144.15M5.53$16.47M-$0.17-38.59

Crinetics Pharmaceuticals currently has a consensus price target of $69.50, indicating a potential upside of 124.27%. Immatics has a consensus price target of $14.67, indicating a potential upside of 123.58%. Given Crinetics Pharmaceuticals' higher probable upside, equities analysts plainly believe Crinetics Pharmaceuticals is more favorable than Immatics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Crinetics Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80
Immatics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20

In the previous week, Crinetics Pharmaceuticals had 5 more articles in the media than Immatics. MarketBeat recorded 7 mentions for Crinetics Pharmaceuticals and 2 mentions for Immatics. Crinetics Pharmaceuticals' average media sentiment score of 1.48 beat Immatics' score of 0.93 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Crinetics Pharmaceuticals
5 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Immatics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Crinetics Pharmaceuticals has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Immatics has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 4.6% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 3.3% of Immatics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Crinetics Pharmaceuticals beats Immatics on 9 of the 17 factors compared between the two stocks.

Get Immatics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMTX vs. The Competition

MetricImmaticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$784.00M$3.06B$5.69B$9.50B
Dividend YieldN/A2.37%4.58%4.01%
P/E Ratio-38.5921.1828.1020.05
Price / Sales5.53288.50432.4490.07
Price / Cash26.4042.7636.2258.56
Price / Book1.288.378.665.87
Net Income$16.47M-$55.19M$3.25B$258.55M
7 Day Performance9.33%5.88%4.23%3.74%
1 Month Performance17.35%17.33%10.52%11.75%
1 Year Performance-46.67%4.42%34.41%18.03%

Immatics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMTX
Immatics
2.805 of 5 stars
$6.56
+1.7%
$14.67
+123.6%
-47.1%$784.00M$144.15M-38.59260News Coverage
Positive News
CRNX
Crinetics Pharmaceuticals
3.685 of 5 stars
$30.95
-0.5%
$69.50
+124.6%
-41.9%$2.91B$1.04M-8.10210Positive News
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
ALVO
Alvotech
2.7142 of 5 stars
$8.64
+0.1%
$16.00
+85.2%
-14.9%$2.60B$491.98M23.351,032
MIRM
Mirum Pharmaceuticals
3.8631 of 5 stars
$51.95
+0.0%
$65.50
+26.1%
+28.4%$2.57B$336.89M-32.27140Positive News
CPRX
Catalyst Pharmaceuticals
4.9239 of 5 stars
$21.01
-0.1%
$32.83
+56.3%
+20.7%$2.57B$491.73M13.3880News Coverage
Positive News
Analyst Revision
GMTX
Gemini Therapeutics
N/A$57.77
0.0%
N/A+36.0%$2.50BN/A-57.7730High Trading Volume
AMRX
Amneal Pharmaceuticals
3.1469 of 5 stars
$7.91
-0.8%
$11.60
+46.6%
+9.2%$2.50B$2.83B-197.708,100
NAMS
NewAmsterdam Pharma
3.5369 of 5 stars
$22.56
+1.6%
$41.30
+83.1%
+26.1%$2.49B$45.56M-12.004
RARE
Ultragenyx Pharmaceutical
4.373 of 5 stars
$26.39
+0.3%
$83.64
+216.9%
-39.3%$2.49B$560.23M-4.491,294Upcoming Earnings
Gap Down
High Trading Volume
OGN
Organon & Co.
4.7712 of 5 stars
$9.43
-0.4%
$18.00
+91.0%
-53.9%$2.46B$6.40B3.274,000

Related Companies and Tools


This page (NASDAQ:IMTX) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners